When to sell JNJ
The honest answer to "when should I sell Johnson & Johnson" is not a price target. It is the moment the reasons you bought it stop being true. Here is a thesis-based checklist for JNJ holders.
The JNJ sell checklist
- 1Did a reason break, or just the price? A drawdown with your thesis intact is not a sell signal. A contradicted pillar is.
- 2Check the latest filing and earnings Read what changed against your reasons for owning JNJ, not against the stock chart.
- 3Look for the specific risks JNJ's known risks are below. Watch for any of them turning from possibility into fact.
- 4Re-underwrite, do not anchor If a reason is gone, decide whether you would buy JNJ today on what remains. If not, the position is a hold by inertia.
What you bought JNJ for
Some investors cite Johnson & Johnson's impressive EPS growth of 90.50% year-over-year as a strong indicator of its profitability and future potential. Additionally, the company has a robust ROE of 32.87%, suggesting effective management and high returns on equity.
The signals that would break it
Conversely, concerns have been raised regarding competition in the pharmaceutical sector, particularly as Johnson & Johnson faces biosimilar competition for its product STELARA, which could impact its future revenue growth. Furthermore, the P/E ratio of 24.20 may suggest that the stock is priced relatively high compared to its earnings.
Where JNJ stands now
Johnson & Johnson has a market capitalization of $648.60B and is currently priced at $266.98, reflecting a 0.23% increase from the previous close of $266.38. The stock's day range was between $261 and $267.13, with a P/E ratio of 24.20 and an EPS growth of 90.50% year-over-year. Additionally, revenue grew by 6.05% year-over-year, and the company maintains a strong ROE of 32.87%. The stock has a 52-week high of $281.01 and a low of $173.47.
The hard part is noticing
Everyone agrees you should sell when the reasons change. The problem is that the evidence lives in filings and earnings calls, while you spend your attention on the price. Helm closes that gap: you write the reasons you own JNJ, and Helm watches the primary sources against them, then tells you with a dated citation when one breaks. See how thesis monitoring works, or read what could invalidate the JNJ thesis.
Common questions
When should I sell JNJ?
Sell Johnson & Johnson when the specific reasons you bought it are contradicted by a filing, an earnings result, or a material news event, not merely when the price falls. A lower price with the thesis intact is a different situation from a broken thesis.
What are the warning signs for JNJ?
The main risks to watch: Conversely, concerns have been raised regarding competition in the pharmaceutical sector, particularly as Johnson & Johnson faces biosimilar competition for its product STELARA, which could impact its future revenue growth. Furthermore, the P/E ratio of 24.20 may suggest that the stock is priced relatively high compared to its earnings.
Is a falling JNJ price a reason to sell?
Not by itself. Price is not a reason. The question is whether the reasons you own JNJ still hold. If they do, a drawdown may be noise; if they do not, the position deserves a fresh decision regardless of price.
Know the moment, not the price.
Helm tells you, with a dated source, when the JNJ thesis breaks. Free to start.
Take the helmThis content is for educational purposes only and does not constitute financial, tax, or investment advice. Helm Terminal is not a registered investment advisor.